Abstract
Human neutrophil proteinase 3 (PR3) and elastase (HNE) are homologous serine proteinases involved in the proteolytic events associated with inflammation and infection. Their close structural and functional resemblance makes it difficult to understand their respective biological functions. Thus, all natural inhibitors of PR3 identified to date preferentially target HNE, and only recently have inhibitors that target PR3 selectively been described. This review describes how differences in the structures of the extended active sites of PR3 and HNE can be exploited to produce selective inhibitors of PR3.
Keywords: Proteinase 3 (myeloblastin), neutrophil, azapeptide, serpin, drug development.
Current Pharmaceutical Design
Title:Selective Inhibitors of Human Neutrophil Proteinase 3
Volume: 19 Issue: 6
Author(s): Brice Korkmaz, Christine Kellenberger, Marie-Claude Viaud-Massuard and Francis Gauthier
Affiliation:
Keywords: Proteinase 3 (myeloblastin), neutrophil, azapeptide, serpin, drug development.
Abstract: Human neutrophil proteinase 3 (PR3) and elastase (HNE) are homologous serine proteinases involved in the proteolytic events associated with inflammation and infection. Their close structural and functional resemblance makes it difficult to understand their respective biological functions. Thus, all natural inhibitors of PR3 identified to date preferentially target HNE, and only recently have inhibitors that target PR3 selectively been described. This review describes how differences in the structures of the extended active sites of PR3 and HNE can be exploited to produce selective inhibitors of PR3.
Export Options
About this article
Cite this article as:
Korkmaz Brice, Kellenberger Christine, Viaud-Massuard Marie-Claude and Gauthier Francis, Selective Inhibitors of Human Neutrophil Proteinase 3, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/1381612811319060002
DOI https://dx.doi.org/10.2174/1381612811319060002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autoantibodies in Systemic Lupus: Quite a Lot or Just a Few?
Current Rheumatology Reviews The Diterpenoids of the Genus Elaeoselinum (Apiaceae) and their Biological Properties
Current Organic Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Pathological Features of Antibody-Mediated Rejection
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Topical Delivery of Antioxidants
Current Drug Delivery Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Magnetic Resonance Angiography and Multidetector CT Angiography in the Diagnosis of Takayasu's Arteritis: Assessment of Disease Extent and Correlation with Disease Activity
Current Medical Imaging Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews The Idiopathic Interstitial Pneumonias and Connective Tissue Disease-Associated Interstitial Lung Disease
Current Rheumatology Reviews Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets